论文部分内容阅读
目的:探讨腺病毒介导的p53与p16基因联合对人肺腺癌GLC-82疗效提高的可能性。方法:将分别携有p53基因、p16基因重组腺病毒(Ad-p53与 Ad-p16)联合使用,通过细胞生长和存活实验、克隆形成实验、流式细胞分析、TUNEL检测、RT-PCR分析、免疫组织化学实验,观察其对人肺腺癌GLC-82细胞的作用。结果:在总感染强度相同的前提下,Ad-p53与Ad-p16联合导入GLC-82细胞,对细胞生长存活及克隆形成能力的抑制、以及所造成的凋亡效果比施用单种基因的效果强,表明p53基因与p16基因在体外疗效上互为协同。结论:Ad-p53与Ad-p16联合,可以提高对人肺腺癌GLC-82细胞的疗效。
Objective: To investigate the possibility of adenovirus-mediated p53 and p16 gene combination therapy on human lung adenocarcinoma GLC-82. Methods: The recombinant adenovirus carrying p53 gene and p16 gene (Ad-p53 and Ad-p16) was used in combination. The cell growth and survival assay, clone formation assay, flow cytometry analysis, TUNEL assay and RT- Immunohistochemistry was used to observe the effect on human lung adenocarcinoma GLC-82 cells. Results: The combination of Ad-p53 and Ad-p16 in GLC-82 cells inhibited the growth and survival of cells and the clonogenic capacity of the cells, and the effect of apoptosis was better than that of the single gene when the total infection intensity was the same Strong, indicating that the p53 gene and p16 gene in vitro synergy. Conclusion: The combination of Ad-p53 and Ad-p16 can improve the therapeutic effect on human lung adenocarcinoma GLC-82 cells.